SAN DIEGO, April 18, 2025 /PRNewswire/ -- òòò½ÊÓƵreminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a "clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need."
For more information, submit a , emailÌý²¹³Ù³Ù´Ç°ù²Ô±ð²â Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations:òòò½ÊÓƵRobbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO
According to the complaint, defendants failed to disclose that in connection with its IPO, Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO. On November 12, 2024, the Company filed with the SEC its quarterly report on Form 10-Q for the period ended September 30, 2024, stating that the Company could fund its operations for the following twelve months, not twenty-four, as it had stated in the Registration Statement. Since the IPO, and as a result of the disclosure of material adverse facts omitted from Zenas BioPharma's Registration Statement, Zenas BioPharma's share price has fallen substantially below its IPO price. As of the close of trading on April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, 48.7% below the IPO price.òòò½ÊÓƵ
What Now: You may be eligible to participate in the class action against Zenas BioPharma, Inc. Sharholders who want to serve as lead plaintiff for the class must file their papers with the court by June 16, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click .
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.òòò½ÊÓƵ
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of òòò½ÊÓƵhave been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.òòò½ÊÓƵ
To be notified if a class action against Zenas BioPharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up foròòò½ÊÓƵÌý³Ù´Ç»å²¹²â.
Attorney Advertising. Past results do not guarantee a similar outcome.
View original content to download multimedia:
SOURCE Robbins LLP
